Extrusion printed polymer structures: A facile and versatile approach to tailored drug delivery platforms

Rattanakit, Parawee; Moulton, Simon E.; Santiago, Karen S.; Liawruangrath, Saisunee; Wallace, Gordon G.

doi:10.1016/j.ijpharm.2011.11.007

Cited by 80 publications

(30 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1e). Semi-solids (gels or pastes) are formulated by mixing optimal ratios of polymers and appropriate solvent(s) in order to obtain a viscosity suitable for printing (81,82). It has a wide range of applications and the availability of bench top platforms further encourages its creative use in rapid prototyping of numerous objects.…”

Section: E Semi-solid Extrusion (Ext) 3d Printingmentioning

confidence: 99%

Emergence of 3D Printed Dosage Forms: Opportunities and Challenges

et al. 2016

View full text Add to dashboard Cite

The recent introduction of the first FDA approved 3D-printed drug has fuelled interest in 3D printing technology, which is set to revolutionize healthcare. Since its initial use, this rapid prototyping (RP) technology has evolved to such as extent that it is currently being used in a wide range of applications including in tissue engineering, dentistry, construction, automotive and aerospace. However, in the pharmaceutical industry this technology is still in its infancy and its potential yet to be fully explored. This paper presents various 3D printing technologies such as stereolithographic, powder based, selective laser sintering, fused deposition modelling and semi-solid extrusion 3D printing. It also provides a comprehensive review of previous attempts at using 3D printing technologies on the manufacturing dosage forms with a particular focus on oral tablets. Their advantages particularly with adaptability in the pharmaceutical field have been highlighted, including design flexibility and control and manufacture which enables the preparation of dosage forms with complex designs and geometries, multiple actives and tailored release profiles. An insight into the technical challenges facing the different 3D printing technologies such as the formulation and processing parameters is provided. Light is also shed on the different regulatory challenges that need to be overcome for 3D printing to fulfil its real potential in the pharmaceutical industry.

show abstract

Section: E Semi-solid Extrusion (Ext) 3d Printingmentioning

confidence: 99%

Emergence of 3D Printed Dosage Forms: Opportunities and Challenges

et al. 2016

View full text Add to dashboard Cite

show abstract

“…73 The use of 3D printing as a flexible alternative method to con-74 ventional tableting techniques was first developed using powder- 75 based 3D printing technologies [5][6][7][8]. Other printing techniques 76 such as inkjet printing [9], thermal inkjet printing [10], piezoelec-77 tric inkjet printing system [11], selective laser sintering [12], stere-78 olithography [13] and syringe/extrusion 3D printing [14] have also 79 been investigated. 80 Fused Deposition Modelling (FDM) is a widely used and afford-81 able bench top 3D printing technique.…”

mentioning

confidence: 99%

A flexible-dose dispenser for immediate and extended release 3D printed tablets

Pietrzak

Isreb

Alhnan

2015

European Journal of Pharmaceutics and Biopharmaceutics

362

202

View full text Add to dashboard Cite

The advances in personalised medicine increased the demand for a fast, accurate and reliable production method of tablets that can be digitally controlled by healthcare staff. A flexible dose tablet system is presented in this study that proved to be suitable for immediate and extended release tablets with a realistic drug loading and an easy-to-swallow tablet design. The method bridges the affordable and digitally controlled Fused Deposition Modelling (FDM) 3D printing with a standard pharmaceutical manufacturing process, Hot Melt Extrusion (HME). The reported method was compatible with three methacrylic polymers (Eudragit RL, RS and E) as well as a cellulose-based one (hydroxypropyl cellulose, HPC SSL). The use of a HME based pharmaceutical filament preserved the linear relationship between the mass and printed volume and was utilized to digitally control the dose via an input from computer software with dose accuracy in the range of 91-95%. Higher resolution printing quality doubled the printing time, but showed a little effect on in vitro release pattern of theophylline and weight accuracy. Physical characterization studies indicated that the majority of the model drug (theophylline) in the 3D printed tablet exists in a crystal form. Owing to the small size, ease of use and the highly adjustable nature of FDM 3D printers, the method holds promise for future individualised treatment.

show abstract

“…The chemical used for the release test is dexamethasone 21-phosphate disodium salt (DPS, C 22 H 28 FNa 2 O 8 P), an anti-inflammatory glucocorticoid. DPS was sandwiched in between polypyrrole film and silicon substrate [27][28][29][30][31][32][33]. The test was carried out by immersing the sample in de-ionized (DI) water over different periods and the concentration of released DPS in water was assessed by the optical absorption spectra peaked in the range of 235 -250 nm [34].…”

Section: A N U S C R I P Tmentioning

confidence: 99%

“…It is a pro-drug that can be converted to dexamethasone (a type of steroid) in vivo. The purchased DPS is in the form of white powder [27][28][29][30][31][32][33][34].…”

Section: Chemical Release Testmentioning

confidence: 99%